Symbols / IMMX $10.18 +5.17% Immix Biopharma, Inc.
IMMX Chart
About
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Fundamentals
Scroll to Statements| Market Cap | 539.66M | Enterprise Value | 439.84M | Income | -29.44M | Sales | — | Book/sh | 1.77 | Cash/sh | 1.90 |
| Dividend Yield | — | Payout | 0.00% | Employees | — | IPO | — | P/E | — | Forward P/E | -13.99 |
| PEG | — | P/S | — | P/B | 5.75 | P/C | — | EV/EBITDA | -14.80 | EV/Sales | — |
| Quick Ratio | 9.93 | Current Ratio | 10.01 | Debt/Eq | 1.14 | LT Debt/Eq | — | EPS (ttm) | -0.89 | EPS next Y | -0.73 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-03-25 | ROA | -29.30% | ROE | -55.00% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 53.01M | Shs Float | 36.45M | Short Float | 7.66% |
| Short Ratio | 3.59 | Short Interest | — | 52W High | 11.61 | 52W Low | 1.66 | Beta | 0.21 | Avg Volume | 827.47K |
| Volume | 583.55K | Target Price | $17.56 | Recom | None | Prev Close | $9.68 | Price | $10.18 | Change | 5.17% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.56
Mean price target
2. Current target
$10.18
Latest analyst target
3. DCF / Fair value
$-4.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.18
Low
$14.80
High
$23.00
Mean
$17.56
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-30 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2026-03-30 | main | Mizuho | Outperform → Outperform | $15 |
| 2026-03-27 | reit | Citizens | Market Outperform → Market Outperform | $23 |
| 2026-03-27 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2026-03-25 | init | Morgan Stanley | — → Overweight | $20 |
| 2026-03-09 | init | Citizens | — → Market Outperform | $23 |
| 2026-02-09 | init | Mizuho | — → Outperform | $14 |
| 2025-12-09 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-09-12 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-06-04 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-06 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-10-03 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-26 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-09 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-01 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2023-08-14 | reit | Roth MKM | Buy → Buy | $14 |
| 2023-02-22 | init | Roth MKM | — → Buy | $14 |
- IMMX (Immix Biopharma Inc.) posts wider Q4 2025 EPS miss, shares edge higher as investors focus on long-term pipeline. - Retail Trader Ideas - UBND thành phố Hải Phòng hu, 23 Apr 2026 01
- Immix fills amyloidosis trial; Q3 results tee up planned FDA filing - Stock Titan Mon, 30 Mar 2026 07
- Immix Biopharma (IMMX) price target increased by 50.00% to 12.24 - MSN Mon, 20 Apr 2026 09
- Immix Biopharma, Inc. Closes $93.7 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative ue, 09 Dec 2025 08
- Immix stock wins Morgan Stanley bullish view (IMMX:NASDAQ) - Seeking Alpha Wed, 25 Mar 2026 07
- We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully - Yahoo Finance Mon, 24 Nov 2025 08
- Citizens reiterates Immix Biopharma stock rating on trial enrollment - Investing.com ue, 31 Mar 2026 07
- IMMX Immix Biopharma posts wider than expected Q4 2025 loss, shares edge lower on investor disappointment. - Earnings Forecast - Xã Thanh Hà Wed, 22 Apr 2026 20
- $IMMX stock is up 9% today. Here's what we see in our data. - Quiver Quantitative ue, 17 Feb 2026 08
- Immix Biopharma (IMMX) sets price for upsized $100M stock and pre-funded warrant offering - Stock Titan Sun, 07 Dec 2025 08
- Immix Biopharma, Inc. (NASDAQ:IMMX) surges 10%; individual investors who own 56% shares profited along with insiders - Yahoo Finance ue, 28 Oct 2025 07
- $IMMX stock is down 9% today. Here's what we see in our data. - Quiver Quantitative Wed, 18 Mar 2026 07
- Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance ue, 09 Dec 2025 08
- Immix Biopharma (IMMX) closes $100M offering, nets $93.7M from biotech funds - Stock Titan ue, 09 Dec 2025 08
- Immix Biopharma to Host Investor Meetings at Jefferies Global Healthcare Conference 2026 - Quiver Quantitative hu, 09 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
29.96
+32.11%
|
22.67
+40.48%
|
16.14
+96.39%
|
8.22
|
| Research And Development |
|
16.26
+43.97%
|
11.29
+29.28%
|
8.74
+108.19%
|
4.20
|
| Selling General And Administration |
|
13.70
+20.35%
|
11.38
+53.68%
|
7.41
+84.09%
|
4.02
|
| General And Administrative Expense |
|
13.70
+20.35%
|
11.38
+53.68%
|
7.41
+84.09%
|
4.02
|
| Other Gand A |
|
13.70
+20.35%
|
11.38
+53.68%
|
7.41
+84.09%
|
4.02
|
| Total Expenses |
|
29.96
+32.11%
|
22.67
+40.48%
|
16.14
+96.39%
|
8.22
|
| Operating Income |
|
-29.96
-32.11%
|
-22.67
-40.48%
|
-16.14
-96.39%
|
-8.22
|
| Total Operating Income As Reported |
|
-29.96
-32.11%
|
-22.67
-40.48%
|
-16.14
-96.39%
|
-8.22
|
| EBITDA |
|
-29.59
-31.17%
|
-22.56
-39.81%
|
-16.14
-96.37%
|
-8.22
|
| Normalized EBITDA |
|
-29.59
-31.17%
|
-22.56
-39.81%
|
-16.14
-96.37%
|
-8.22
|
| Reconciled Depreciation |
|
0.36
+215.89%
|
0.12
+2010.24%
|
0.01
+156.11%
|
0.00
|
| EBIT |
|
-29.96
-32.11%
|
-22.67
-40.48%
|
-16.14
-96.39%
|
-8.22
|
| Total Unusual Items |
|
—
|
—
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-29.44
-36.21%
|
-21.61
-40.11%
|
-15.43
-87.44%
|
-8.23
|
| Pretax Income |
|
-29.40
-35.75%
|
-21.66
-39.10%
|
-15.57
-89.42%
|
-8.22
|
| Net Non Operating Interest Income Expense |
|
0.56
-45.40%
|
1.02
+77.86%
|
0.57
+115191.75%
|
-0.00
|
| Interest Expense Non Operating |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Net Interest Income |
|
0.56
-45.40%
|
1.02
+77.86%
|
0.57
+115191.75%
|
-0.00
|
| Interest Expense |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Interest Income Non Operating |
|
0.56
-45.40%
|
1.02
+77.86%
|
0.57
|
0.00
|
| Interest Income |
|
0.56
-45.40%
|
1.02
+77.86%
|
0.57
|
0.00
|
| Other Income Expense |
|
—
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
—
|
| Tax Provision |
|
0.04
-8.07%
|
0.04
+55.35%
|
0.03
+157.26%
|
0.01
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-29.44
-35.67%
|
-21.70
-39.13%
|
-15.60
-89.50%
|
-8.23
|
| Net Income From Continuing Operation Net Minority Interest |
|
-29.44
-36.21%
|
-21.61
-40.11%
|
-15.43
-87.44%
|
-8.23
|
| Net Income From Continuing And Discontinued Operation |
|
-29.44
-36.21%
|
-21.61
-40.11%
|
-15.43
-87.44%
|
-8.23
|
| Net Income Continuous Operations |
|
-29.44
-35.67%
|
-21.70
-39.13%
|
-15.60
-89.50%
|
-8.23
|
| Minority Interests |
|
0.00
-100.00%
|
0.08
-49.85%
|
0.17
|
0.00
|
| Normalized Income |
|
-29.44
-36.21%
|
-21.61
-40.11%
|
-15.43
-87.44%
|
-8.23
|
| Net Income Common Stockholders |
|
-29.44
-36.21%
|
-21.61
-40.11%
|
-15.43
-87.44%
|
-8.23
|
| Diluted EPS |
|
—
|
-0.76
+14.61%
|
-0.89
-50.85%
|
-0.59
|
| Basic EPS |
|
—
|
-0.76
+14.61%
|
-0.89
-50.85%
|
-0.59
|
| Basic Average Shares |
|
—
|
28.29
+63.11%
|
17.34
+24.87%
|
13.89
|
| Diluted Average Shares |
|
—
|
28.29
+63.11%
|
17.34
+24.87%
|
13.89
|
| Diluted NI Availto Com Stockholders |
|
-29.44
-36.21%
|
-21.61
-40.11%
|
-15.43
-87.44%
|
-8.23
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
104.84
+356.86%
|
22.95
+15.17%
|
19.93
+33.65%
|
14.91
|
| Current Assets |
|
101.24
+401.23%
|
20.20
+2.07%
|
19.79
+32.82%
|
14.90
|
| Cash Cash Equivalents And Short Term Investments |
|
100.41
+467.86%
|
17.68
+0.98%
|
17.51
+30.31%
|
13.44
|
| Cash And Cash Equivalents |
|
93.93
+431.21%
|
17.68
+0.98%
|
17.51
+30.31%
|
13.44
|
| Cash Financial |
|
—
|
—
|
17.51
+30.31%
|
13.44
|
| Other Short Term Investments |
|
6.48
|
0.00
|
—
|
—
|
| Receivables |
|
0.00
-100.00%
|
1.97
+68.44%
|
1.17
+358.41%
|
0.26
|
| Taxes Receivable |
|
0.00
-100.00%
|
1.97
+68.44%
|
1.17
+358.41%
|
0.26
|
| Prepaid Assets |
|
0.68
+33.06%
|
0.51
-52.01%
|
1.06
-5.87%
|
1.13
|
| Other Current Assets |
|
0.15
+367.05%
|
0.03
-27.61%
|
0.04
-42.89%
|
0.08
|
| Total Non Current Assets |
|
3.60
+31.00%
|
2.75
+1901.34%
|
0.14
+1236.15%
|
0.01
|
| Net PPE |
|
3.49
+27.80%
|
2.73
+5339.55%
|
0.05
+1309.58%
|
0.00
|
| Gross PPE |
|
3.78
+36.18%
|
2.78
+4205.57%
|
0.06
+1711.66%
|
0.00
|
| Accumulated Depreciation |
|
-0.29
-520.04%
|
-0.05
-230.13%
|
-0.01
|
—
|
| Properties |
|
0.00
|
0.00
|
0.00
|
—
|
| Buildings And Improvements |
|
0.97
-2.28%
|
0.99
|
0.00
|
—
|
| Machinery Furniture Equipment |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
—
|
| Construction In Progress |
|
0.00
-100.00%
|
0.94
|
0.00
|
—
|
| Other Properties |
|
1.57
+85.38%
|
0.84
+1293.98%
|
0.06
+1602.22%
|
0.00
|
| Leases |
|
1.24
|
0.00
|
—
|
—
|
| Non Current Deferred Assets |
|
0.09
|
0.00
-100.00%
|
0.09
+1197.28%
|
0.01
|
| Other Non Current Assets |
|
0.02
+0.00%
|
0.02
|
—
|
0.01
|
| Total Liabilities Net Minority Interest |
|
11.04
+13.90%
|
9.70
+160.54%
|
3.72
+112.88%
|
1.75
|
| Current Liabilities |
|
10.11
+16.39%
|
8.69
+133.41%
|
3.72
+192.30%
|
1.27
|
| Payables And Accrued Expenses |
|
9.03
+13.38%
|
7.96
+153.31%
|
3.14
+146.91%
|
1.27
|
| Payables |
|
5.44
+1.01%
|
5.39
+276.02%
|
1.43
+901.59%
|
0.14
|
| Accounts Payable |
|
5.44
+1.01%
|
5.39
+276.02%
|
1.43
+901.59%
|
0.14
|
| Current Accrued Expenses |
|
3.59
+39.26%
|
2.58
+50.52%
|
1.71
+51.38%
|
1.13
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.94
+43.15%
|
0.66
+13.90%
|
0.58
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.14
+113.65%
|
0.07
|
—
|
—
|
| Current Debt |
|
—
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.14
+113.65%
|
0.07
|
0.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.93
-7.52%
|
1.01
|
0.00
-100.00%
|
0.47
|
| Long Term Debt And Capital Lease Obligation |
|
0.93
-7.52%
|
1.01
|
0.00
|
—
|
| Long Term Capital Lease Obligation |
|
0.93
-7.52%
|
1.01
|
0.00
|
—
|
| Long Term Provisions |
|
—
|
—
|
—
|
0.47
|
| Stockholders Equity |
|
93.80
+607.83%
|
13.25
-19.23%
|
16.41
+24.66%
|
13.16
|
| Common Stock Equity |
|
93.80
+607.83%
|
13.25
-19.23%
|
16.41
+24.66%
|
13.16
|
| Capital Stock |
|
0.01
+91.93%
|
0.00
+38.10%
|
0.00
+43.16%
|
0.00
|
| Common Stock |
|
0.01
+91.93%
|
0.00
+38.10%
|
0.00
+43.16%
|
0.00
|
| Preferred Stock |
|
—
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
53.02
+92.03%
|
27.61
+38.10%
|
19.99
+43.18%
|
13.96
|
| Ordinary Shares Number |
|
52.95
+92.27%
|
27.54
+38.24%
|
19.92
+43.41%
|
13.89
|
| Treasury Shares Number |
|
0.07
+0.00%
|
0.07
+0.00%
|
0.07
+0.00%
|
0.07
|
| Additional Paid In Capital |
|
198.29
+124.38%
|
88.37
+26.65%
|
69.78
+36.40%
|
51.16
|
| Retained Earnings |
|
-104.46
-39.24%
|
-75.02
-40.47%
|
-53.41
-40.61%
|
-37.99
|
| Gains Losses Not Affecting Retained Earnings |
|
0.06
+5796.97%
|
-0.00
-100.78%
|
0.13
+54.75%
|
0.09
|
| Treasury Stock |
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
|
| Minority Interest |
|
0.00
|
0.00
+100.00%
|
-0.20
|
0.00
|
| Other Equity Adjustments |
|
0.06
+5796.97%
|
-0.00
-100.78%
|
0.13
+54.75%
|
0.09
|
| Total Equity Gross Minority Interest |
|
93.80
+607.83%
|
13.25
-18.22%
|
16.20
+23.13%
|
13.16
|
| Total Capitalization |
|
93.80
+607.83%
|
13.25
-19.23%
|
16.41
+24.66%
|
13.16
|
| Working Capital |
|
91.13
+691.67%
|
11.51
-28.35%
|
16.07
+17.92%
|
13.62
|
| Invested Capital |
|
93.80
+607.83%
|
13.25
-19.23%
|
16.41
+24.66%
|
13.16
|
| Total Debt |
|
1.07
-0.17%
|
1.07
|
0.00
|
—
|
| Capital Lease Obligations |
|
1.07
-0.17%
|
1.07
|
0.00
|
—
|
| Net Tangible Assets |
|
93.80
+607.83%
|
13.25
-19.23%
|
16.41
+24.66%
|
13.16
|
| Tangible Book Value |
|
93.80
+607.83%
|
13.25
-19.23%
|
16.41
+24.66%
|
13.16
|
| Current Notes Payable |
|
—
|
—
|
—
|
0.00
|
| Interest Payable |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-23.93
-63.96%
|
-14.60
-28.35%
|
-11.37
-53.50%
|
-7.41
|
| Cash Flow From Continuing Operating Activities |
|
-23.93
-63.96%
|
-14.60
-28.35%
|
-11.37
-53.50%
|
-7.41
|
| Net Income From Continuing Operations |
|
-29.44
-35.67%
|
-21.70
-39.13%
|
-15.60
-89.50%
|
-8.23
|
| Depreciation Amortization Depletion |
|
0.36
+215.89%
|
0.12
+2010.24%
|
0.01
+156.11%
|
0.00
|
| Depreciation |
|
0.36
+215.89%
|
0.12
+2010.24%
|
0.01
+156.11%
|
0.00
|
| Depreciation And Amortization |
|
0.36
+215.89%
|
0.12
+2010.24%
|
0.01
+156.11%
|
0.00
|
| Other Non Cash Items |
|
—
|
—
|
—
|
0.10
|
| Stock Based Compensation |
|
2.44
-19.16%
|
3.02
+17.73%
|
2.57
+311.13%
|
0.62
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
2.70
-31.89%
|
3.97
+140.02%
|
1.65
+746.75%
|
0.20
|
| Change In Receivables |
|
2.06
+311.99%
|
-0.97
-8.74%
|
-0.89
-277.94%
|
-0.24
|
| Change In Prepaid Assets |
|
-0.29
-151.68%
|
0.55
+396.03%
|
0.11
+116.18%
|
-0.69
|
| Change In Payables And Accrued Expense |
|
1.03
-76.66%
|
4.40
+80.80%
|
2.43
+116.85%
|
1.12
|
| Change In Accrued Expense |
|
—
|
—
|
0.00
+100.00%
|
-0.01
|
| Change In Payable |
|
1.03
-76.66%
|
4.40
+80.80%
|
2.43
+115.11%
|
1.13
|
| Change In Account Payable |
|
1.03
-76.66%
|
4.40
+80.80%
|
2.43
+115.11%
|
1.13
|
| Change In Other Current Assets |
|
0.00
+100.00%
|
-0.02
|
0.00
|
—
|
| Change In Other Current Liabilities |
|
-0.10
-3536.40%
|
0.00
|
0.00
|
—
|
| Investing Cash Flow |
|
-7.21
-512.54%
|
-1.18
-2160.90%
|
-0.05
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
-7.21
-512.54%
|
-1.18
-2160.90%
|
-0.05
|
0.00
|
| Net PPE Purchase And Sale |
|
-0.73
+37.77%
|
-1.18
-2160.90%
|
-0.05
|
0.00
|
| Purchase Of PPE |
|
-0.73
+37.77%
|
-1.18
-2160.90%
|
-0.05
|
0.00
|
| Capital Expenditure |
|
-0.73
+37.77%
|
-1.18
-2160.90%
|
-0.05
|
—
|
| Net Investment Purchase And Sale |
|
-6.48
|
0.00
|
—
|
—
|
| Purchase Of Investment |
|
-6.48
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
107.39
+573.33%
|
15.95
+3.14%
|
15.46
+378.44%
|
3.23
|
| Cash Flow From Continuing Financing Activities |
|
107.39
+573.33%
|
15.95
+3.14%
|
15.46
+378.44%
|
3.23
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.05
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.05
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Short Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.05
|
| Net Short Term Debt Issuance |
|
—
|
—
|
0.00
+100.00%
|
-0.05
|
| Net Common Stock Issuance |
|
107.39
+573.47%
|
15.95
+1.60%
|
15.70
+377.24%
|
3.29
|
| Common Stock Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.10
|
| Repurchase Of Capital Stock |
|
—
|
—
|
0.00
+100.00%
|
-0.10
|
| Proceeds From Stock Option Exercised |
|
0.13
+5168.86%
|
0.00
-4.93%
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
-0.14
|
—
|
-0.23
-3389.23%
|
-0.01
|
| Changes In Cash |
|
76.24
+43272.74%
|
0.18
-95.65%
|
4.04
+196.74%
|
-4.18
|
| Effect Of Exchange Rate Changes |
|
0.00
+206.07%
|
-0.00
-110.95%
|
0.03
+204.97%
|
-0.03
|
| Beginning Cash Position |
|
17.68
+0.98%
|
17.51
+30.31%
|
13.44
-23.85%
|
17.64
|
| End Cash Position |
|
93.93
+431.21%
|
17.68
+0.98%
|
17.51
+30.31%
|
13.44
|
| Free Cash Flow |
|
-24.66
-56.37%
|
-15.77
-38.07%
|
-11.42
-54.20%
|
-7.41
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.01
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Change In Interest Payable |
|
—
|
—
|
0.00
+100.00%
|
-0.01
|
| Common Stock Issuance |
|
107.39
+573.47%
|
15.95
+1.60%
|
15.70
+363.17%
|
3.39
|
| Issuance Of Capital Stock |
|
107.39
+573.47%
|
15.95
+1.60%
|
15.70
+363.17%
|
3.39
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-30 View
- 8-K2026-03-25 View
- 10-K2026-03-25 View
- 42025-12-11 View
- 42025-12-10 View
- 42025-12-10 View
- 8-K2025-12-08 View
- 8-K2025-12-08 View
- 8-K2025-11-26 View
- 10-Q2025-11-07 View
- 42025-09-17 View
- 42025-09-17 View
- 8-K2025-09-08 View
- 10-Q2025-08-08 View
- 8-K2025-06-23 View
- 42025-06-23 View
- 42025-06-23 View
- 42025-06-23 View
- 42025-06-23 View
- 42025-06-23 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|